Compare MBUU & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBUU | ETON |
|---|---|---|
| Founded | 1982 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.3M | 510.1M |
| IPO Year | 2013 | 2018 |
| Metric | MBUU | ETON |
|---|---|---|
| Price | $26.08 | $23.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | $32.43 | ★ $39.33 |
| AVG Volume (30 Days) | 295.9K | ★ 354.0K |
| Earning Date | 05-07-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.74 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $807,561,000.00 | $79,950,000.00 |
| Revenue This Year | $1.44 | $34.30 |
| Revenue Next Year | $10.67 | $36.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $24.07 | $11.09 |
| 52 Week High | $39.65 | $24.46 |
| Indicator | MBUU | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 41.10 | 71.77 |
| Support Level | $24.43 | $16.38 |
| Resistance Level | $34.66 | N/A |
| Average True Range (ATR) | 0.96 | 1.30 |
| MACD | 0.28 | 0.43 |
| Stochastic Oscillator | 46.02 | 82.71 |
Malibu Boats is a designer and manufacturer of power boats in the United States. It is a market leader in performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a producer of sterndrive boats, in 2017, and Pursuit Boats, which makes high end offshore and outboard motorboats in 2018. In 2021, it purchased Maverick Boat Group, a seller of flat fishing boats, with exposure to bay, dual console, and center console boats. Malibu has also expanded into boat trailers and accessories, and in 2020, began producing its own engines for its performance sport boats.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.